Omega Fund Management, LLC Buys Theseus Pharmaceuticals Inc, Sells Atea Pharmaceuticals Inc, Cidara Therapeutics Inc, Paratek Pharmaceuticals Inc

Feb 15, 2022

Investment company Omega Fund Management, LLC (Current Portfolio) buys Theseus Pharmaceuticals Inc, sells Atea Pharmaceuticals Inc, Cidara Therapeutics Inc, Paratek Pharmaceuticals Inc, ObsEva SA, Trevi Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Omega Fund Management, LLC. As of 2021Q4, Omega Fund Management, LLC owns 22 stocks with a total value of $707 million. These are the details of the buys and sells.

New Purchases: THRX,
Reduced Positions: NUVB, MORF, REPL, PRTK, GOSS,
Sold Out: AVIR, CDTX, OBSV, TRVI, FGEN,

For the details of Omega Fund Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/omega+fund+management%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Omega Fund Management, LLC

Nuvation Bio Inc (NUVB) - 22,957,340 shares, 27.59% of the total portfolio. Shares reduced by 18.63%
Replimune Group Inc (REPL) - 4,763,380 shares, 18.25% of the total portfolio. Shares reduced by 2.71%
Imago BioSciences Inc (IMGO) - 3,018,737 shares, 10.12% of the total portfolio.
Morphic Holding Inc (MORF) - 1,200,014 shares, 8.04% of the total portfolio. Shares reduced by 8.81%
Kronos Bio Inc (KRON) - 3,818,283 shares, 7.34% of the total portfolio.

New Purchase: Theseus Pharmaceuticals Inc (THRX)

Omega Fund Management, LLC initiated holding in Theseus Pharmaceuticals Inc. The purchase prices were between $8.98 and $20.09, with an estimated average price of $15.08. The stock is now traded at around $11.810000. The impact to a portfolio due to this purchase was 1.28%. The holding were 711,479 shares as of 2021-12-31.

Sold Out: Atea Pharmaceuticals Inc (AVIR)

Omega Fund Management, LLC sold out a holding in Atea Pharmaceuticals Inc. The sale prices were between $7.67 and $44.59, with an estimated average price of $14.96.

Sold Out: Cidara Therapeutics Inc (CDTX)

Omega Fund Management, LLC sold out a holding in Cidara Therapeutics Inc. The sale prices were between $1.18 and $1.96, with an estimated average price of $1.54.

Sold Out: ObsEva SA (OBSV)

Omega Fund Management, LLC sold out a holding in ObsEva SA. The sale prices were between $1.99 and $3.01, with an estimated average price of $2.4.

Sold Out: Trevi Therapeutics Inc (TRVI)

Omega Fund Management, LLC sold out a holding in Trevi Therapeutics Inc. The sale prices were between $0.68 and $1.5, with an estimated average price of $1.04.

Sold Out: FibroGen Inc (FGEN)

Omega Fund Management, LLC sold out a holding in FibroGen Inc. The sale prices were between $9.93 and $15.39, with an estimated average price of $12.54.

Here is the complete portfolio of Omega Fund Management, LLC. Also check out:

1. Omega Fund Management, LLC's Undervalued Stocks
2. Omega Fund Management, LLC's Top Growth Companies, and
3. Omega Fund Management, LLC's High Yield stocks
4. Stocks that Omega Fund Management, LLC keeps buying

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Data is updated daily.